Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza

Impact of the number of repeated inhalations and patient characteristics on the residual amount of inhaled laninamivir octanoate hydrate dry powder in pediatric patients with influenza

Abstract Background A dry powder inhaled formulation is used for the anti-influenza drug laninamivir octanoate hydrate (laninamivir). Although two successive inhalations (puffs) are recommended to minimize residual amounts of active ingredients, previous reports suggest that pediatric patients with...

Full description

Bibliographic Details
Main Authors: Toshiki Murasaka, Kenji Ikemura, Tomoyuki Enokiya, Yuichi Muraki, Mayumi Ikemura, Koji Terada, Takuya Iwamoto, Masahiro Okuda
Format: Article
Language:English
Published: BMC 2017-11-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Inhalation
Influenza
Laninamivir
Peak inspiratory flow
Pediatric patients
Online Access:http://link.springer.com/article/10.1186/s40780-017-0094-7

Internet

http://link.springer.com/article/10.1186/s40780-017-0094-7

Similar Items